Attached files
| file | filename |
|---|---|
| EX-99.02 - EXHIBIT 99.2 - MEDICINES CO /DE | exhibit992.htm |
| EX-99.01 - EXHIBIT 99.1 - MEDICINES CO /DE | pressreleaseq12016-q12016.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
____________
FORM 8‑K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 9, 2016
The Medicines Company |
(Exact Name of Registrant as Specified in Charter) |
Delaware | 000-31191 | 04-3324394 | ||
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
8 Sylvan Way Parsippany, New Jersey | 07054 | |
(Address of Principal Executive Offices) | (Zip Code) | |
Registrant's telephone number, including area code: (973) 290-6000
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02. Results of Operations and Financial Condition.
On May 9, 2016 The Medicines Company (the “Company”) announced financial results for the three months ended March 31, 2016. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 8.01. Other Events.
On May 9, 2016, the Company issued a press release announcing the execution of a Purchase and Sale Agreement with Chiesi USA, Inc. and its parent company, Chiesi Farmaceutici S.p.A. The full text of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The information in this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
99.1 | Press release dated May 9, 2016 entitled “The Medicines Company Reports First-Quarter 2016 Business and Financial Results” |
99.2 | Press release dated May 9, 2016 entitled “The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THE MEDICINES COMPANY
Date: May 9, 2016
By: /s/ Stephen Rodin
Stephen M. Rodin
Senior Vice President and General Counsel
Exhibit Index
Exhibit No. | Description |
99.1 | Press release dated May 9, 2016 entitled “The Medicines Company Reports First-Quarter 2016 Business and Financial Results” |
99.2 | Press release dated May 9, 2016 entitled “The Medicines Company Agrees to Divest Non-Core Cardiovascular Assets to Chiesi Farmaceutici S.p.A.” |